MONTREAL and CHARLOTTE, N.C., Nov. 25, 2024 (GLOBE NEWSWIRE) — Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is excited to announce that its President and CEO, Joe Oliveto, alongside Chief Commercial Officer, Lorenz Muller, will engage in an insightful fireside chat at the highly anticipated Piper Sandler 36th Annual Healthcare Conference. Scheduled for December 4, 2024, this session will commence at 10:30 a.m. Eastern Time, providing a unique opportunity for attendees to gain insights from leading figures in the biopharmaceutical industry.
A live webcast of this enlightening fireside chat will be made available to all conference participants, allowing a broader audience to join the discussion. If you wish to view the fireside chat or arrange a meeting with the Milestone team during the conference, please reach out by emailing [email protected].
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a pioneering biopharmaceutical company committed to the development and commercialization of innovative cardiovascular therapies. Our mission is to enhance the quality of life for individuals grappling with complex and life-altering heart conditions. By prioritizing a deep understanding of unmet patient needs and enhancing the overall patient experience, we are dedicated to devising new treatment approaches that empower patients to actively participate in managing their health. Central to our efforts is our lead investigational product, etripamil, a novel calcium channel blocker nasal spray. This game-changing treatment is being studied for self-administration without medical supervision, aimed at effectively managing episodic attacks related to PSVT and AFib-RVR.
Contact:
Kim Fox,
Vice President, Communications,
[email protected]
Investor Relations
Chris Calabrese, [email protected]
Kevin Gardner, [email protected]
What are the key innovations being developed by Milestone Pharmaceuticals to address cardiovascular conditions?
**Interview with Joe Oliveto, President and CEO of Milestone Pharmaceuticals Inc.**
**Interviewer**: Thank you for joining us today, Joe. Milestone Pharmaceuticals has been making strides in innovative cardiovascular therapies. Could you tell us what attendees can expect from your fireside chat at the Piper Sandler 36th Annual Healthcare Conference?
**Joe Oliveto**: Thank you for having me. During our session, I will be discussing our latest developments and the direction of our company in addressing the needs of patients with complex cardiovascular conditions. It’s a great opportunity to share insights not only about our innovations but also about how we are committed to enhancing patient experiences in this challenging area of healthcare.
**Interviewer**: It sounds promising! What specific topics will you cover during the chat?
**Joe Oliveto**: We plan to dive into our current and upcoming clinical programs, share successes we’ve seen with our therapies, and discuss the broader industry landscape. Lorenz Muller, our Chief Commercial Officer, will also contribute valuable perspectives on market strategies and patient engagement.
**Interviewer**: It’s exciting to hear about collaboration at leadership levels. Given the nature of the conversation, how important is patient feedback to Milestone Pharmaceuticals’ mission?
**Joe Oliveto**: Patient feedback is crucial for us. We prioritize understanding unmet needs and the overall patient experience when developing our treatments. Engaging with patients helps us refine our approach and ensures that we’re delivering solutions that truly make a difference in their lives.
**Interviewer**: For those who cannot attend the conference in person, is there a way for them to still engage with your presentation?
**Joe Oliveto**: Absolutely! We will be hosting a live webcast of the fireside chat, which allows a broader audience to join in and benefit from the discussion. We really want to make our insights accessible to as many people as possible.
**Interviewer**: That’s fantastic! One last question: how do you see Milestone Pharmaceuticals evolving in the next few years?
**Joe Oliveto**: We envision a future where our innovative therapies provide meaningful improvements in the lives of patients with cardiovascular conditions. We are committed to continued research and development, focusing on cutting-edge solutions that empower patients. Our excitement about what lies ahead is driven by our dedication to transforming cardiovascular care.
**Interviewer**: Thank you for your time, Joe. We look forward to the fireside chat and all the insights you and your team will share at the conference!
**Joe Oliveto**: Thank you! I’m looking forward to it as well.
For those interested in attending the fireside chat or discussing further opportunities with Milestone Pharmaceuticals, you can reach out via email for arrangements [[1](https://www.globenewswire.com/news-release/2024/05/31/2891478/0/en/Milestone-Pharmaceuticals-to-Participate-in-the-Upcoming-Jefferies-Global-Healthcare-Conference.html)].
